Document is current
Any future updates will be listed below
-
Authors
Chen, Leo Tianlai https://orcid.org/0000-0003-0706-5731
Quinn, Zachary
Dumas, Madeleine https://orcid.org/0000-0002-9749-6203
Peng, Christina https://orcid.org/0000-0001-7471-9059
Hong, Lauren https://orcid.org/0000-0002-1675-4806
Lopez-Gonzalez, Moises
Mestre, Alexander
Watson, Rio
Vincoff, Sophia
Zhao, Lin https://orcid.org/0000-0002-1678-7763
Wu, Jianli
Stavrand, Audrey
Schaepers-Cheu, Mayumi
Wang, Tian Zi
Srijay, Divya
Monticello, Connor
Vure, Pranay
Pulugurta, Rishab
Pertsemlidis, Sarah
Kholina, Kseniia
Goel, Shrey
DeLisa, Matthew P.
Chi, Jen-Tsan Ashley
Truant, Ray
Aguilar, Hector C. https://orcid.org/0000-0001-6879-8360
Chatterjee, Pranam https://orcid.org/0000-0003-3957-8478
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R21CA278468, 3U54CA231630-01A1S4)
Krembil Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI109022)
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 2 July 2025
First Online: 13 August 2025
Competing interests
: L.T.C. and P.C. are co-inventors on US patent applications 63/673,900 (‘Systems and methods for generating peptide binders via masked language modeling’) and 63/673,911 (‘Compositions for the targeted degradation of a protein and methods of making and using same’). P.C. and M.P.D. are co-founders of UbiquiTx, Inc., and are inventors of patents related to genetically encoded proteome editing technologies. The other authors declare no competing interests.
